Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TransCon CNP in Infants With Achondroplasia
NCT06079398Phase 2Recruiting
- Sponsor
- Ascendis Pharma
- Start
- Jan 2024
- Primary completion
- Dec 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 15
01
Overview
A Phase 2 trial of navepegritide in achondroplasia (ACH), sponsored by Ascendis Pharma. Started Jan 2024; status: recruiting.
02
Drugs
navepegritide
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on NCT06079398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06079398.